XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
Total
LINICO
Haywood
Tysadco private placement funding
Common Stock
Common Stock
Haywood
Common Stock
Tysadco private placement funding
Additional Paid in Capital
Additional Paid in Capital
LINICO
Additional Paid in Capital
Haywood
Additional Paid in Capital
Tysadco private placement funding
Accumulated Deficit
Treasury Stock
Non-Controlling Interest
Non-Controlling Interest
LINICO
Beginning balance (in shares) at Dec. 31, 2021         71,207,832                    
Beginning balance at Dec. 31, 2021 $ 92,970,522       $ 47,065     $ 338,936,145       $ (245,542,688) $ (3,870,000) $ 3,400,000  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Common stock received and cancelled in the rescission of the LPB transaction (in shares)         (3,500,000)                    
Common stock received and cancelled in the rescission of the LPB transaction (5,110,000)       $ (2,331)     (5,107,669)              
Capital contribution to LINICO by Aqua Metals   $ 500,000             $ 176,695           $ 323,305
Common stock issuance costs (70,000)             (70,000)              
Employee and director share-based compensation 108,599       $ 119     108,480              
Sales of treasury shares (1,485 common shares) 2,721             805         1,916    
Net loss (6,547,023)                     (6,378,555)   (168,468)  
Ending balance (in shares) at Mar. 31, 2022         67,707,832                    
Ending balance at Mar. 31, 2022 81,854,819       $ 44,853     334,044,456       (251,921,243) (3,868,084) 3,554,837  
Beginning balance (in shares) at Dec. 31, 2021         71,207,832                    
Beginning balance at Dec. 31, 2021 92,970,522       $ 47,065     338,936,145       (245,542,688) (3,870,000) 3,400,000  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Net loss (20,637,620)                            
Ending balance (in shares) at Jun. 30, 2022         76,822,049                    
Ending balance at Jun. 30, 2022 75,435,607       $ 50,923     341,709,771       (265,688,089) (3,868,084) 3,231,086  
Beginning balance (in shares) at Dec. 31, 2021         71,207,832                    
Beginning balance at Dec. 31, 2021 92,970,522       $ 47,065     338,936,145       (245,542,688) (3,870,000) 3,400,000  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Sales of treasury shares (1,485 common shares) $ 240,077                            
Ending balance (in shares) at Dec. 31, 2022 91,442,018       91,442,018                    
Ending balance at Dec. 31, 2022 $ 56,363,459       $ 60,660     348,390,556       (291,491,432) (3,360,867) 2,764,542  
Beginning balance (in shares) at Mar. 31, 2022         67,707,832                    
Beginning balance at Mar. 31, 2022 81,854,819       $ 44,853     334,044,456       (251,921,243) (3,868,084) 3,554,837  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Investment in joint ventures (in shares)           1,500,000 3,076,923                
Capital contribution to LINICO by Aqua Metals     $ 2,295,000 $ 2,000,000   $ 999 $ 2,049     $ 2,294,001 $ 1,997,951        
Issuance of common stock (in shares)         4,377,697                    
Issuance of common stock 3,460,000       $ 2,916     3,457,084              
Issuance of common stock for stock issuance costs (in shares)         829,597                    
Issuance of common stock for stock issuance costs 840,000       $ 553     839,447              
Common stock issuance costs (1,053,000)             (1,053,000)              
Common stock received and cancelled in connection with employee termination (in shares)         (720,000)                    
Common stock received and cancelled in connection with employee termination 0       $ (480)     480              
Employee and director share-based compensation 113,580             113,580              
Repurchase of employee stock options (12,195)             (12,195)              
Exercise of employee stock options (in shares)         50,000                    
Exercise of employee stock options 28,000       $ 33     27,967              
Net loss (14,090,597)                     (13,766,846)   (323,751)  
Ending balance (in shares) at Jun. 30, 2022         76,822,049                    
Ending balance at Jun. 30, 2022 $ 75,435,607       $ 50,923     341,709,771       (265,688,089) (3,868,084) 3,231,086  
Beginning balance (in shares) at Dec. 31, 2022 91,442,018       91,442,018                    
Beginning balance at Dec. 31, 2022 $ 56,363,459       $ 60,660     348,390,556       (291,491,432) (3,360,867) 2,764,542  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Issuance of common stock (in shares)         6,090,276                    
Issuance of common stock 2,150,000       $ 4,056     2,145,944              
Issuance of common stock for stock issuance costs (in shares)         963,445                    
Issuance of common stock for stock issuance costs 350,000       $ 642     349,358              
Common stock issuance costs (607,620)             (607,620)              
Issuance of common stock for conversion of debt and accrued interest (in shares)         4,539,413                    
Issuance of common stock for conversion of debt and accrued interest 1,662,723       $ 3,023     1,659,700              
Employee and director share-based compensation 126,288       $ 120     126,168              
LINICO dividends earned by AQMS not distributed   (44,703)                         (44,703)
Net loss (5,681,742)                     (5,668,937)   (12,805)  
Ending balance (in shares) at Mar. 31, 2023         103,035,152                    
Ending balance at Mar. 31, 2023 $ 54,318,405       $ 68,501     352,064,106       (297,160,369) (3,360,867) 2,707,034  
Beginning balance (in shares) at Dec. 31, 2022 91,442,018       91,442,018                    
Beginning balance at Dec. 31, 2022 $ 56,363,459       $ 60,660     348,390,556       (291,491,432) (3,360,867) 2,764,542  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Net loss $ (11,186,331)                            
Ending balance (in shares) at Jun. 30, 2023 105,876,509       105,876,509                    
Ending balance at Jun. 30, 2023 $ 51,090,491       $ 70,393     354,384,981       (302,628,857) (3,360,867) 2,624,841  
Beginning balance (in shares) at Mar. 31, 2023         103,035,152                    
Beginning balance at Mar. 31, 2023 54,318,405       $ 68,501     352,064,106       (297,160,369) (3,360,867) 2,707,034  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Issuance of common stock (in shares)         619,352                    
Issuance of common stock 500,000       $ 412     499,588              
Issuance of common stock for conversion of debt and accrued interest (in shares)         1,951,248                    
Issuance of common stock for conversion of debt and accrued interest 1,668,932       $ 1,300     1,667,632              
Issuance of common stock in lieu of payment of interest (in shares)         270,757                    
Issuance of common stock in lieu of payment of interest 107,507       $ 180     107,327              
Employee and director share-based compensation 46,328             46,328              
LINICO dividends earned by AQMS not distributed   $ (46,092)                         $ (46,092)
Net loss $ (5,504,589)                     (5,468,488)   (36,101)  
Ending balance (in shares) at Jun. 30, 2023 105,876,509       105,876,509                    
Ending balance at Jun. 30, 2023 $ 51,090,491       $ 70,393     $ 354,384,981       $ (302,628,857) $ (3,360,867) $ 2,624,841